Echo-LVMI Ups Risk Prediction for Cardiovascular Disease

This article originally appeared here.
Share this content:
Echo-LVMI Ups Risk Prediction for Cardiovascular Disease
Echo-LVMI Ups Risk Prediction for Cardiovascular Disease

MONDAY, Aug. 29, 2016 (HealthDay News) -- Left ventricular mass indexed to body size (LV mass index [echo-LMVI]) can improve cardiovascular disease (CVD) risk prediction in older adults, according to a study published in the Sept. 1 issue of The American Journal of Cardiology.

Chintan S. Desai, M.D., from the Johns Hopkins Hospital in Baltimore, and colleagues examined whether LV mass and geometry contribute to CVD risk prediction in adults aged ≥65 years. Echo-LVMI and LV geometry (defined as normal, concentric remodeling, and eccentric or concentric LV hypertrophy) were added to separate 10-year risk prediction models, and the net reclassification improvement (NRI) was determined for incident coronary heart disease (CHD), cardiovascular disease (CHD, heart failure, and stroke), and heart failure alone.

The researchers found that, in 2,577 participants, the adjusted hazard ratios for a one-standard deviation higher echo-LVMI were 1.25, 1.24, and 1.51, respectively, for CHD, CVD, and heart failure alone, over 10 years of follow-up. The event NRI was −0.011 and the nonevent NRI was 0.034 with addition of echo-LMVI to the standard model for CHD. The event NRI was 0.013 and the nonevent NRI was 0.043 for addition of echo-LMVI and LV geometry to the standard model for CVD. With addition of echo-LVMI, the nonevent NRI was also significant for heart failure risk prediction (0.10).

"In conclusion, in adults aged ≥65 years, echo-LVMI improved risk prediction for CHD, CVD, and heart failure, driven primarily by improved reclassification of nonevents," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

ASH: Synthetic Blood Cell Passes Proof-of-Concept Testing

ASH: Synthetic Blood Cell Passes Proof-of-Concept Testing

Synthetic product made from purified human hemoglobin proteins coated with a synthetic polymer

Fewer School Shootings in States With Tighter Gun Laws

Fewer School Shootings in States With Tighter Gun ...

Study also found that states that spent more money on mental health care, education saw less violence

SABCS: No Survival Benefit Seen for Letrozole Beyond Five Years

SABCS: No Survival Benefit Seen for Letrozole Beyond ...

Study found women who continued with letrozole did experience other benefits, however

is free, fast, and customized just for you!

Already a member?

Sign In Now »